Has the clinical definition of thromboangiitis obliterans changed indeed?

Barlas, Semih; Elmaci, Türkan; Dayıoğlu, Enver; Alpagut, Ufuk; Onursal, Ertan; Kargi, Aydin; Barlas, Cemil

doi:10.1055/s-0031-1276037

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other studies, common symptoms were superficial thrombophlebitis, claudication, ulcer, and coldness. [20][21][22][23] The results of this study showed that C3 and C4 were normal in 55.70 and 77.22% of patients, respectively. Moreover, 51.25% had normal CH50 values.…”

Section: Discussionmentioning

confidence: 95%

Humoral and cellular immune response to Buerger’s disease

et al. 2020

View full text Add to dashboard Cite

Objective Thromboangiitis obliterans is a nonatherosclerotic occlusive disease, affecting small to moderate sized arteries of the upper and lower extremities, leading to progressive inflammation and clot formation. However, the role of humoral and cell-mediated immunity in the development of this disease has not been clearly identified. The present study was intended to investigate the humoral and cellular immune response in patients with Buerger’s disease with different disease severity. Methods In an observational study, 80 male patients with Buerger’s disease were included and categorized into three groups (mild, moderate, and severe) based on clinical manifestations. After blood sampling, cellular phenotypes were determined, and erythrocyte sedimentation rate, immunoglobulins (Ig) A, M, G, and E, as well as C3 and C4 components of the complement system and complement hemolytic activity (CH50) were measured. Results The mean age of the patient was 42.85 ± 8.39 years. Pulse abnormality, cold intolerance, and claudication were the most common symptoms. Eleven (13.75%), 46 (57.50%), and 23 (28.75%) patients had mild, moderate, and severe symptoms. Regression analyses showed that the presence of severe symptoms was significantly associated with elevated erythrocyte sedimentation rate and C4 levels ( p < 0.05). Conclusion Buerger’s disease in severe cases was associated with increased erythrocyte sedimentation rate and abnormal C4 levels. The alterations in these inflammatory biomarkers might be due to a secondary inflammatory response to the presence of ulcer or gangrene and the inflammatory process in patients with severe symptoms.

show abstract

Section: Discussionmentioning

confidence: 95%

Humoral and cellular immune response to Buerger’s disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…One of early symptoms are leg claudications, the necessity for frequent resting, mild swelling in extremities and ischemic ulcers on the fingers and toes. A significant number of patients have superficial thrombophlebitis and paresthesia, while more than 80% of patients have changes on 3 to 4 extremities (9,10,11).…”

Section: Clinical Featuresmentioning

confidence: 99%

Advancements in mesenchymal stem cell treatment for Buerger's disease

Pavlović¹,

Fazlagić²,

Lozuk³

et al. 2017

Medicinska istraživanja

View full text Add to dashboard Cite

Buerger's disease or thromboangiitis obliterans, is a non-atherosclerotic inflammatory process which mostly involves medium and small sized arteries and veins in lower and upper extremities. It is categorized as vasculitis. The disease is known to be closely linked to smoking. Buerger's disease is a long-term debilitating condition because of the pain, the development of ulcers and gangrene, and the risk of amputation. Drugs effective on erythrocyte flexibility, agents acting on platelets, non-steroidal anti-inflammatory drugs and vascular reconstruction are among several therapeutic methods for Buerger's disease. However, the applied therapies are insufficiently effective. Still, the base of treatment is smoking cessation. Lately, cell therapy has offered us entirely new possibilities. Mesenchymal stem cell (MSC) treatment has been proposed as a novel approach for tissue engineering and regenerative medicine for various ischemic disorders, including Buerger's disease. In 2016, the first MSC based therapy has received regulatory approval for the treatment of Buerger's disease in India. In March 2017, orphan designation was granted by the European Commission for autologous adipose tissue-derived MSC for the treatment of Buerger's disease. Novel therapeutic approach needs to be validated in the upcoming studies conducted in different clinical centers.

show abstract

Has the clinical definition of thromboangiitis obliterans changed indeed?

Cited by 2 publications

References 21 publications

Humoral and cellular immune response to Buerger’s disease

Humoral and cellular immune response to Buerger’s disease

Advancements in mesenchymal stem cell treatment for Buerger's disease

Contact Info

Product

Resources

About